DTIL vs. RNAC, TNYA, FHTX, LFCR, PBYI, AVTE, VOR, VTYX, ZURA, and KYTX
Should you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Cartesian Therapeutics (RNAC), Tenaya Therapeutics (TNYA), Foghorn Therapeutics (FHTX), Lifecore Biomedical (LFCR), Puma Biotechnology (PBYI), Aerovate Therapeutics (AVTE), Vor Biopharma (VOR), Ventyx Biosciences (VTYX), Zura Bio (ZURA), and Kyverna Therapeutics (KYTX). These companies are all part of the "pharmaceutical products" industry.
Precision BioSciences vs. Its Competitors
Precision BioSciences (NASDAQ:DTIL) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.
Cartesian Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -6,205.79%. Cartesian Therapeutics' return on equity of 0.00% beat Precision BioSciences' return on equity.
Precision BioSciences has higher revenue and earnings than Cartesian Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.
38.0% of Precision BioSciences shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 4.0% of Precision BioSciences shares are owned by company insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Precision BioSciences has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500.
Precision BioSciences currently has a consensus target price of $47.00, suggesting a potential upside of 745.32%. Cartesian Therapeutics has a consensus target price of $40.00, suggesting a potential upside of 321.50%. Given Precision BioSciences' higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Cartesian Therapeutics.
In the previous week, Precision BioSciences had 4 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 8 mentions for Precision BioSciences and 4 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.62 beat Precision BioSciences' score of 0.40 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.
Summary
Cartesian Therapeutics beats Precision BioSciences on 10 of the 16 factors compared between the two stocks.
Get Precision BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Precision BioSciences Competitors List
Related Companies and Tools
This page (NASDAQ:DTIL) was last updated on 10/14/2025 by MarketBeat.com Staff
